Aravax Announces Positive Results of Phase 2 Clinical Trial of PVX108, a Novel Immunotherapy for the Treatment of Peanut Allergy
Primary endpoint achieved: PVX108 therapy increased the maximum tolerated dose of peanut compared to
Primary endpoint achieved: PVX108 therapy increased the maximum tolerated dose of peanut compared to